EFFECT OF DENOSUMAB ON CLINICAL AND RADIOLOGICAL CHANGES IN RHEUMATOID ARTHRITIS: PRELIMINARY RESULTS
Current therapy for rheumatoid arthritis (RA) should not only suppress inflammation, but should also prevent local and generalized bone mineral density (BMD) loss. The drug of choice to treat secondary osteoporosis (OP) is denosumab, a monoclonal antibody, which binds RANKL, inhibiting the inte...
Main Authors: | P. S. Dydykina, Е. V. Petrova, I. S. Dydykina, A. V. Smirnov, S. V. Glukhova, L. I. Alekseeva, E. L. Nasonov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA-PRESS LLC
2015-04-01
|
Series: | Научно-практическая ревматология |
Subjects: | |
Online Access: | https://rsp.mediar-press.net/rsp/article/view/2066 |
Similar Items
-
CHANGES OF CLINICAL AND RADIOGRAPHIC PARAMETERS DURING DENOSUMAB THERAPY IN RHEUMATOID ARTHRITIS PATIENTS RECEIVING GLUCOCORTICOIDS: PRELIMINARY RESULTS
by: P. S. Dydykina, et al.
Published: (2015-09-01) -
Experience with denosumab therapy for osteoporosis in rheumatoid arthritis patients receiving glucocorticoids
by: I. S. Dydykina, et al.
Published: (2018-06-01) -
Comparative evaluation of denosumab efficacy of in patients with rheumatoid arthritis and postmenopausal osteoporosis: results of 1-year study in clinical practice
by: O. V. Dobrovolskaya, et al.
Published: (2019-05-01) -
Association between bone mineral density and erosive and destructive changes in patients with rheumatoid arthritis: Preliminary results
by: E V Petrova, et al.
Published: (2014-05-01) -
Compliance and discontinuation of denosumab treatment in postmenopausal Japanese women with primary osteoporosis or rheumatoid arthritis and osteoporosis
by: Takako Suzuki, et al.
Published: (2017-06-01)